Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
23 January, 2019 01:18 IST
Cadila Healthcare's JV facility of Zydus Hopsira Oncology receives EIR from USFDA
Source: IRIS | 12 Jul, 2018, 01.23PM
Comments  |  Post Comment

Cadila Healthcare announced that the manufacturing facility of Zydus Hopsira Oncology, a 50:50 joint venture company between Zydus Cadila and Hospira Inc., USA (now part of Pfizer Group) at Ahmedabad has received an Establishment Inspection Report (EIR) from the USFDA which concluded that the inspection is "closed" and states that the inspection classification of this facility is 'Voluntary Action Indicated' (VAI). The manufacturing plant had completed the USFDA audit from April 5 to 12, 2018.

Shares of the company declined Rs 3, or 0.81%, to trade at Rs 368.50. The total volume of shares traded was 107,976 at the BSE (1.09 p.m., Thursday).



Cadila Healthcare Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
LIC completes 51% controlling acquisition in IDBI Bank - 22-Jan-2019 10:25
Lupin receives FDA approval for Levothyroxine Sodium Tablets USP - 21-Jan-2019 17:08
Zydus gets tentative approval from USFDA for Esomeprazole Magnesium Delayed-Release - 21-Jan-2019 16:10
SBI witnessed overwhelming response for its USD 1.25 mn bonds issue - 21-Jan-2019 10:57
HDFC Bank Q3 earnings grow 20% to Rs 55.85 bn - 21-Jan-2019 10:54
BHEL and Libcoin in dialogue to build India's first lithium ion factory - 21-Jan-2019 10:32
BHEL to set up solar electric vehicle chargers along Delhi-Chandigarh highway - 21-Jan-2019 10:28
Wockhardt receives USFDA approval for Leukemia drug - 21-Jan-2019 10:20
Ratnamani Metals & Tubes receives order worth Rs 2 bn - 18-Jan-2019 15:59
Aurobindo Pharma to acquire portfolio of oncology injectables products - 18-Jan-2019 13:47
Reliance Ind Q3 earnings up 8.8%; GRM's at USD 8.8/bbl - 18-Jan-2019 13:08
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer